Biocytogen and Whitehawk Therapeutics Enter Global Collaboration for Bispecific Antibody ADC Development

Summary

Biocytogen and Whitehawk Therapeutics announced a global collaboration for the development of bispecific antibody ADCs (antibody-drug conjugates). The partnership focuses on leveraging both companies' capabilities in antibody and ADC technology.